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Hypertension is the most common chronic condition seen by physicians in ambulatory care and a 
condition for which life-long medications are commonly prescribed. There is evidence for genetic 
factors influencing blood pressure variation in populations and response to medications. This 
review summarizes recent genetic discoveries that surround blood pressure, hypertension, and 
antihypertensive drug response from genome-wide association studies, while highlighting 
ancestry-specific findings and any potential implication for drug therapy targets. Genome-wide 
association studies have identified several novel loci for inter-individual variation of blood 
pressure and hypertension risk in the general population. Evidence from pharmacogenetic studies 
suggests that genes influence the blood pressure response to antihypertensive drugs, although 
results are somewhat inconsistent across studies. There is still much work that remains to be done 
to identify genes both for efficacy and adverse events of antihypertensive medications.
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Introduction
Hypertension is the most common chronic condition seen by physicians in ambulatory care 
[1] and a condition for which life-long medications are commonly prescribed. In the USA, 
hypertension affects one-third of the adult population, has increased among children and 
adolescents, affecting disproportionally some ethnic/racial subgroups [2, 3]. From the 
clinical and public health perspective, the major long-term impact of hypertension is 
resultant end-organ damage to the kidneys, heart, vessels, and brain, leading to premature 
mortality, disability, and significantly increased economic and societal cost [4–6]. Evidence 
from clinical trials has shown that lowering blood pressure reduces the risk of stroke, 
coronary heart disease, and mortality [7–12], in addition to slowing the progression of 
chronic kidney disease [13]. African Americans are a subgroup who suffer a greater burden 
of hypertension and its complications, and are more likely to have uncontrolled hypertension 
[14] and to require multiple drugs for blood pressure (BP) control compared with other US 
racial/ethnic subgroups [15]. Genetic factors also contribute to hypertension and may 
interact with environmental exposures (including pharmacological agents) and social-
lifestyle habits in contributing to disparities in hypertension prevalence and severity 
observed across diverse race/ethnic subgroups.
This review summarizes recent genetic discoveries that surround BP, hypertension, and 
antihypertensive drug response from studies of the general population and those from 
pharmacogenomic settings, while highlighting ancestry-specific findings and any potential 
implication for drug therapy targets. We focused on discovery efforts seeking (1) loci 
contributing to the inter-individual variation in BP and hypertension risk using large-scale 
genetic approaches, including genome-wide association studies (GWAS), applied to cohorts 
of individuals recruited from the general population, and (2) loci identified through GWAS 
of pharmacologic traits, including those related to clinical response to antihypertensive 
medications. The first approach is an unbiased scan of the entire genome aiming to provide 
insights into the genes contributing to the biology of BP regulation, to suggest targets for 
therapy and for population-level risk reduction. The second approach focuses specifically on 
identifying genetic variants influencing drug response, including drugs used for the 
treatment of hypertension, and/or genetic variants associated with side effects of drugs. 
Pharmacogenetics holds the promise of providing individualized clinical care, by identifying 
subgroups based on their response to commonly used drugs for hypertension and/or 
subgroups at higher risk for harmful side-effects of drugs and thus tailoring therapy to an 
individual’s genetic makeup. Although both approaches have already identified numerous 
genes related to BP, hypertension, and antihypertensive drug response, the functional 
variants underlying most associations remain largely unknown and much work is still needed 
to translate the findings to the clinical care of patients.
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Blood Pressure Loci Identified in Studies of the General Population
Common Variants Identified in GWAS and Admixture Models
The heritability of BP is substantial (in the range of 30–55 %), suggesting a large number of 
contributing genetic variants, the vast majority of which are yet to be discovered [16•, 17]. 
Genetic analysis of Mendelian, i.e., extreme forms of hypertension and hypotension, has 
highlighted some pathways of BP regulation in humans and these findings comprise rare 
genetic variants with large impact in BP [17, 18]. However, identifying genes related to 
common variation in BP and essential hypertension has proven challenging. Hypertension—
and its response to treatment—is a complex trait that is likely influenced by a large number 
of genetic variants, each with small effects, and possibly modulated by environmental 
factors including diet, lifestyle, and other exposures. Recent genetic discovery efforts for this 
class of genetic variation have focused on unbiased scans of the genome for associations 
with BP traits using data from individuals recruited from the general population, a 
proportion of them having essential hypertension. This GWAS approach examines the 
association of hundreds of thousands of genetic markers commonly seen in the population 
(single-nucleotide polymorphisms, SNPs), and relies on stringent statistical criteria for 
discovery of loci in order to account for multiple testing (typically p<5 × 10−8). Validation 
of genomic regions is further provided by replication of the associations in additional 
samples. Because genetic variants vary in allele frequency across race/ethnicity and the 
patterns of correlation among genetic markers also vary by ancestry and admixture, studies 
are performed within each ancestrally homogenous group separately.
The first two BP GWAS [19, 20] discovered 13 BP loci and were followed by a combined 
effort from the International Consortia of Blood Pressure (ICBP) [16•] reporting additional 
associations for a total of 28 loci for systolic and diastolic BP and/or hypertension. 
Subsequent studies reported over 55 loci for BP in GWAS of pulse pressure and mean 
arterial pressure [21], GWAS using extremes of the BP distribution or hypertension [22, 23], 
and in studies using gene-centric arrays, which provide a better genomic coverage for some 
loci [24–26]. The identified genetic variants from GWAS have small effects and explained 
only a small proportion of the trait variation. For example, 29 SNPs in the 28 loci identified 
in ICBP explained less than 1 % of the inter-individual variation in BP [16•]. However, 
findings from GWAS have already uncovered some biology and potential targets for drug 
therapy (discussed under “Genes, Pathways, and Potential Role for Pharmacogenetics”).
The ICBP and several other recently published studies have studied mostly individuals of 
European ancestry [16•, 19, 20, 22–25, 27]. Studies of non-European ancestry including 
East Asians [28•, 29] and African ancestry [30, 31•] have contributed additional information 
to the genetic architecture of BP, though their sample sizes are limited. For example, a 
GWAS of BP in East Asians identified four novel BP loci, and evidence for an ethnic-
specific variant at ALDH2 (aldehyde dehydrogenase 2). The ALDH2 variant was highly 
correlated with a known functional variant (rs671), which was previously associated with 
hypertension modulated by alcohol intake in East Asians [28•].
Individuals of African ancestry have more genomic diversity and less linkage disequilibrium 
(correlations among SNPs) compared with European and Asian populations [32]. These 
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genomic differences can be helpful in gene discovery and also in narrowing genomic regions 
within identified loci to identify functional variants for BP. Using admixture mapping 
approaches followed by association analyses, Zhu et al. [30] Identified the NPR3 (natriuretic 
peptide receptor 3) locus for systolic and diastolic BP in African Americans, subsequently 
shown to be associated with BP traits in individuals of European ancestry [16•] and East 
Asians [28•]. In a recent meta-analysis of 19 GWAS of African ancestry participants of the 
Continental Origins and Genetic Epidemiology Network Blood Pressure (COGENT-BP) 
consortium, three novel loci for BP (EVX1-HOXA, RSPO3, PLEKHG1) [31•] were 
identified, although the discovery sample (including 29,000 individuals) was half of the 
ICBP sample, thus highlighting the potential for differences according to ancestry. RSPO3 
(R-spondin 3)-encoded protein activates the Wnt/beta-catenin signaling pathways, and the 
locus has been previously associated with blood urea nitrogen levels, a measure of kidney 
function [33]. There was also evidence for an additional novel variant at the previously 
reported locus SOX6. Of interest, genetic loci identified in individuals of African ancestry 
replicated across European and East Asian individuals in a trans-ethnic meta-analysis. 
Therefore, studies of non-European ancestry are essential for trans-ethnic gene discovery, as 
common genetic variants may have broad effects across ancestries in the population.
Rare Variants Influencing BP Traits
In addition to common genetic variants, recent studies have shown that low frequency 
variants (minor allele frequency between 0.5 and 5 %) [34] can have large effects and may 
explain some of the missing heritability of complex traits [35]. Importantly, rare variants 
constitute the vast majority of polymorphic sites in human populations [34]. Low-frequency 
and population-specific variants are not well captured by current GWAS genotyping 
platforms, particularly among non-European ancestry populations. Studies of low frequency 
variants using sequencing data and 1000 Genomes Project imputed data are ongoing, and 
examples of loci associations with BP traits have not yet been published. However, a 
candidate gene sequencing study identified rare variants in kidney solute transporters, all of 
which are targets for diuretics, which were associated with low BP in the Framingham Heart 
Study [36]. These included variants in the SLC12A3 (thiazide-sensitive Na-Cl cotransporter, 
the target of thiazide diuretics), SLC12A1 (Na-K-Cl cotransporter NKCC2, the target of 
loop diuretics furosemide and bumetanide) and KCNJ1 (K+ channel ROMK) genes [36]. 
Because rare variants tend to be population-specific [37], future studies may provide 
evidence for ancestry-specific variants at low frequency influencing the genetic architecture 
of BP traits.
Genes, Pathways, and Potential Role for Pharmacogenetics
Most genomic regions identified in BP GWAS include genes of unknown function, but some 
loci include genes known or suspected to be involved in BP pathways and/or are targets of 
antihypertensive drugs (Table 1). The CYP17A1 (cytochrome P450 enzyme) protein is a key 
enzyme in the steroidogenic pathway that produces mineralocorticoids and glucocorticoids, 
and rare Mendelian mutations manifest by congenital adrenal hyperplasia and hypokalemic 
hypertension [38]. This locus has been identified in GWAS of both European and East Asian 
individuals [16•, 28•]. The ADM (adrenomedullin) protein is a hypotensive peptide found in 
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human pheochromocytoma [39], a disease manifested by paroxysmal hypertension and a 
cause of secondary hypertension [40]. ADRB1 encodes the β-1 adrenergic receptor, a 
guanine nucleotide-binding regulatory protein-coupled receptor target of β-adrenergic 
receptor blockers. SNPs nearby or within the gene have been associated with mean arterial 
pressure in GWAS [21] and a lower risk of essential hypertension [41]. Vasoactive peptides 
including natriuretic peptides and endothelin have a well-known role in BP control. Several 
genes in these pathways have been identified in GWAS of BP including NPPA/NPPB 
(precursors of atrial- and B-type natriuretic peptides), NPR3 (natriuretic peptide clearance 
receptor), and EDN3 (endothelin 3). Soluble guanylyl cyclase, the product of the 
GUCY1A3-GUCY1B3 genes, generates cyclic guanosine monophosphate (cGMP) under 
stimulation by nitric oxide, inducing vasodilation. NOS3 encodes nitric oxide synthase 3, 
which is responsible for the conversion of l-arginine to the vasodilator nitric oxide. Several 
calcium and potassium channel genes have been identified in GWAS of BP traits including 
ATP2B1, CACNB2 and KCNJ11, and their pharmacologic targets are shown in Table 1. 
Genes related to the rennin-angiotensin-aldosterone system identified in BP GWAS are 
ENPEP, which encodes a glytamyl aminopeptidase involved in the conversion of angiotensin 
II to angiotensin III, and AGT, which encodes angiotensinogen precursor, the target of renin 
conversion to angiotensin I. FURIN encodes a protease involved in the processing of protein 
precursors including the prorenin receptor. Except for AGT, the effect of polymorphisms in 
these genes in response to therapy has not been studied. AGT variants have been also shown 
to interact with a low-salt diet [42, 43].
Kidney Genes, BP and Hypertension
The role of the kidneys on BP homeostasis is well-defined through mechanisms related to 
salt reabsorption and volume control. BP GWAS identified two kidney solute transporters, 
SLC4A7 (electro-neutral sodium bicarbonate co-transporter) and SLC39A8 (solute carrier 
family 39 [zinc transporter], member 8), but their role in BP regulation remains unknown 
[16•]. SLC39A8 is the major transporter of cadmium into cells in humans, an environmental 
metal pollutant that has been associated with endothelial dysfunction, oxidative stress, and 
hypertension in populations [44–47].
UMOD (uromodulin) is highly expressed in the kidney’s thick ascending limb and encodes 
the Tamm-Horsfall protein, the most abundant protein excreted in normal urine. In GWAS, 
variants in the promoter of UMOD (rs4293393, rs13333226) associated with lower BP and 
with a better kidney function [23, 48]. Transgenic mice with overexpression of uromodulin 
manifest salt-sensitive hypertension, aging-related kidney pathology, and activation of the 
thick ascending limb sodium cotransporter NKCC2, the target of loop diuretics [49]. 
Hypertensive individuals homozygous for UMOD at risk variant rs4293393 demonstrated a 
lowering of BP salt sensitivity response when treated with furosemide compared to other 
hypertensive individuals [49]. rs4293393 is common in all ethnic groups represented in 
HapMap and the 1000 Genomes Project, suggesting a potential role in hypertension across 
diverse ancestry groups.
Chronic kidney disease is usually accompanied by hypertension. A gene known to cause 
chronic kidney disease and secondary hypertension is APOL1 (apolipoprotein L, 1), recently 
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reviewed in this journal [50]. Two APOL1 alleles, under positive selection in populations of 
African ancestry, confer substantial risk of focal segmental glomerulosclerosis, HIV-
associated nephropathy and hypertensive-attributed nephropathy [51–53]. This is also an 
example of ancestry-specific variants common in the population that present risk for 
hypertension.
GWAS Findings and Drug Repositioning
Sauseau et al. recently examined the utility of GWAS data in identifying drug targets or 
alternative clinical indications for existing drugs [54]. Using a set of 991 GWAS genes 
identified from publications listed in the genome catalog up to 2011, they found that 21 % of 
the genes were amenable to pharmacological modulation using small molecules and 47 % 
using biopharmaceuticals, which was a significantly higher frequency than those derived 
from the whole genome. In addition, by combining their gene list with a list obtained from 
the Pharmaprojects database (www.pharmaprojects.com), 155 genes were identified that 
were already targets or in development for a clinical disease. By matching drugs and clinical 
GWAS traits, the authors were able to identify potential novel indications for existing drugs 
or drugs in development. These data suggest that GWAS findings are enriched for “drug-
able” genes in humans, even though the functional variants may not yet have been identified.
GWAS and Hypertension Drug Targets
Johnson et al. studied the association of gene targets of alpha blockers, angiotensin-
converting enzyme inhibitors, beta blockers, angiotensin receptor blockers, calcium channel 
blockers, diuretics, and vasodilators, identified in the DrugBank (www.drugbank.ca), with 
BP and hypertension using GWAS [27]. Genetic variants within 60 kb of 30 drug target 
genes were selected and tested for associations with BP and hypertension traits in the 
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium (n 
= 29,136). Replication was performed in over 57,000 European ancestry individuals. The 
study found associations of a nonsynonymous variant in the ADRB1 gene with systolic and 
diastolic BP, and hypertension, and a variant in AGT was associated with systolic BP and 
hypertension [27].
Loci Identified in Pharmacogenetic Studies
Pharmacologic exposures can modify the effects of genes influencing BP and contribute to 
antihypertensive response and overall cardiovascular risk. Genetic factors can influence the 
response to pharmacologic agents and/or can guide treatment strategies such as avoiding 
side-effects and other harmful complications. Despite the promise of pharmacogenomics in 
the treatment of hypertensive patients, their use is still limited in clinical care. Given the 
complex regulatory mechanisms for BP, alternative strategies for the investigation of BP 
genes may prove informative for gene finding, for example, BP responses to pharmacologic 
interventions [55]. Recent GWAS for antihypertensive pharmacogenetics have identified 
NEDD4L (neural precursor cell expressed, developmentally downregulated 4-like) variants 
that are associated with antihypertensive response to diuretics [56–58, 66], as well as 
PRKCA variants influencing BP response to thiazide diuretics [59•] (discussed below).
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The pharmacogenetics of antihypertensive treatment has been recently summarized [60, 61]. 
Evidence from studies suggests that genetics influence the BP response to antihypertensive 
drugs, although results are somewhat inconsistent across studies. Comparison of findings 
across studies is complicated by differences in study design, methods for assessing BP, 
pharmacologic exposures (including dose and duration), and small sample size. 
Pharmacogenetic studies of BP response and antihypertensive drug side effects can be found 
in the International Consortium for Antihypertensive Pharmacogenetic Studies (ICAPS) at 
www.pharmgkb.org/page/icaps. These studies include observational studies and clinical 
trials of antihypertensive drugs, and used candidate gene and GWAS genetic approaches. 
Below, we focus on findings from GWAS.
GWAS Studies of BP Drug Response
Two GWAS of BP drug response were recently published [59•, 62•]. These studies used data 
from randomized clinical trials. Gong et al. studied the association of SNPs in 37 BP GWAS 
loci (Illumina 50 K cardiovascular or Omni 1 M GWAS arrays) with response to atenolol 
and thiazide diuretics in 461 European and 298 African-ancestry hypertensive participants of 
the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, a 
multicenter, randomized clinical trial of hydrochlorothiazide (HCTZ) versus atenolol [62•]. 
Although there was no genome-wide significant finding when corrected for multiple testing, 
a genetic risk score based on nominally significant associations in the array-wide analysis 
was significantly associated with response to atenolol and thiazides in individuals of 
European ancestry. Turner et al. studied the association of common variants influencing 
antihypertensive response to HCTZ in 424 hypertensive European Americans from the 
PEAR study and the Genetic Epidemiology of Responses to Antihypertensive (GERA) study 
[59•]. Among ∼1.1 million genetic markers tested, an SNP in PRKCA (rs16960228) was 
associated with greater systolic and diastolic BP response among carriers of the allele A, 
reaching genome-wide significance in a combined metaanalysis of discovery and additional 
replication samples. An SNP nearby GNAS-EDN3 (rs2273359), although replicated in 
independent samples, did not reach the genome-wide threshold for significance for BP 
response to HCTZ.
He et al. performed a GWAS of BP in response to dietary intervention and cold pressor test 
in 1,881 Han Chinese participants from the GenSalt study [63]. The GenSalt study included 
a 7-day low-sodium (51.3 mmol/d), a 7-day high-sodium (307.8 mmol/d), and a 7-day high-
sodium plus potassium supplementation (60 mmol/d) diet intervention in addition to BP cold 
pressor test response. They identified eight novel loci that were associated with one or more 
traits and replicated in an additional sample of 698 Han Chinese individuals. These included 
SNPs in or near PRMT6, CDCA7, and PIBF1, which were associated with response to low-
salt diet; IRAK1BP1 associated with high-sodium intervention; CDCA7, ARL4C, 
IRAK1BP1, and SALL1, associated with potassium supplementation; and TRPM8 and 
FBXL13 associated with cold pressor test response. In five of these loci, the SNPs were low-
frequency markers (MAF 0.01 to 0.05). The effect sizes were higher than the ones seen in 
GWAS of BP, suggesting stronger genetic effects to response to interventions. Finally, there 
was a strong dose–response relationship between the cumulative allele count and the 
development of hypertension at follow-up.
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GWAS Studies of Adverse Response to Antihypertensive Drugs
GWAS studies of adverse response to antihypertensive drugs have also been recently 
published. Del-Aguilla et al. studied the association of genetic markers with change in 
fasting plasma glucose and triglycerides in response to HCTZ using data from the PEAR 
and GERA studies [64]. They identified two genome-wide significant variants (rs12279250 
and rs4319515) in the NELL1 gene associated with increased fasting triglycerides in African 
Americans. Each at-risk variant allele was associated with a large effect of approximately 28 
mg/dl increase in plasma triglyceride levels. Using 33 SNPs previously associated with 
fasting glucose in white individuals, Gong et al. studied their association with drug-induced 
glucose changes in the PEAR study [65]. An SNP in the 5’ of the PROX1 gene (rs340874) 
was significantly associated with atenolol-induced glucose change, with a 2.39 mg/dl 
increase in serum glucose per each copy of the C-allele. A GWAS of atenolol-induced HDL-
C changes in the PEAR study was not significant [66], although 13 regions showed 
consistent associations among whites and African Americans. These included seven loci 
previously related to lipid pathways or metabolic traits including GALNT2, FTO, ABCB1, 
LRP5, STARD3NL, ESR1, and LIPC. A study of angiotensin-converting enzyme inhibitor-
associated angioedema (175 cases and 489 controls) failed to identify genome-wide 
significant SNPs associated with this complication [67]. In the INternational VErapamil SR 
Trandolapril Study (INVEST), a prospective, randomized study comparing two 
pharmacotherapy strategies to control hypertension in ambulatory patients with coronary 
artery disease, TCF7L2 polymorphisms were associated with HCTZ-induced diabetes [68].
Taken together, although GWAS published studies are still limited, their findings suggest 
genetic effects for common variants in drug-induced side-effects. Nonetheless, GWAS 
discovery studies of BP drug response are limited by small sample size and are likely too 
underpowered to identify novel loci.
Ancestry and Choice of Hypertension Medications
A recent report from the authors originally convened as the 8th Joint National Committee 
[69] recommends different first-line for antihypertensive drugs in African-American 
compared to non-African-American hypertensive individuals (a calcium channel blocker or 
thiazide-type diuretics). Based on evidence from the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT) clinical trials [70], in which black 
individuals taking a thiazide diuretic showed better stroke, heart failure, and combined 
cardiovascular outcomes compared to those taking an ACE inhibitor. For the non-African-
American population, the new report recommends an angiotensin-converting enzyme 
inhibitor, angiotensin receptor blocker, a calcium channel blocker or thiazide-type diuretic as 
first-line therapy. African Americans have greater increases in BP in response to sodium 
intake, i.e., salt sensitivity [71, 72]. A recent study by Tu et al. showed that increases in BP 
in African-American children and adults were associated with increased plasma aldosterone 
concentration and reduction in plasma renin activity [73]. This relationship was not seen in 
white individuals. African-American individuals also had higher BP response to an 
intervention using the synthetic mineralocorticoid 9-α-fludrocortisone, suggesting 
aldosterone sensitivity as a mechanism of hypertension [73]. It is likely that there is an 
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underlying genetic component that explains the racial/ethnic differences in response to 
therapy seen in clinical trials, although findings are yet to be published.
Future Research and Clinical Perspectives
While some progress has occurred recently in the search for genes contributing to the 
response to antihypertensive therapy, both in terms of efficacy and adverse events, there is 
much work that remains to be done. A challenge for researchers in the field is replication of 
significant findings in a different study population. Not only are trials expensive to conduct, 
there are few antihypertensive trials that are active and collecting DNA. Another challenge is 
the need to replicate findings with the same drug or even the same drug class. The recent 
formation of the ICAPS (International Consortium for Antihypertensive Pharmacogenetic 
Studies) is a step forward towards replication. A second major challenge is the lack of trans-
ethnic GWAS to identify common targets across ancestries. Finally, there is currently an 
absence of validated genome-based measures with sufficient clinical utility to be 
implemented in clinical practice.
Conclusions
GWAS have identified over 55 loci associated with blood pressure and hypertension traits. 
These loci harbor genes that are either established or potential targets for antihypertensive 
drugs. Studies of non-European ancestry are important to leverage trans-ethnic gene 
discovery, and to narrow down genomic regions where putative genetic variants (common or 
rare) are located. Although there is evidence for genes influencing the blood pressure 
response to antihypertensive drugs, few pharmacogenetic GWAS of antihypertensive drugs 
have been reported. Challenges for these studies are their small sample sizes, the lack of 
ancestry diversity, and difficulties in finding replication samples.
Acknowledgments
Funding NIHU01- GM074492 (to RKCD)
References
Papers of particular interest, published recently, have been highlighted as:
• Of importance
1. Ashman JJ, Beresovsky V. Multiple chronic conditions among us adults who visited physician 
offices: data from the national ambulatory medical care survey, 2009. Prev Chronic Dis. 2013; 
10:E64. [PubMed: 23618544] 
2. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension 
in the us adult population. Results from the third national health and nutrition examination survey, 
1988–1991. Hypertension. 1995; 25:305–313. [PubMed: 7875754] 
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: 
heart disease and stroke statistics-2014 update: a report from the American Heart Association. 
Circulation. 2014; 129:399–410. [PubMed: 24446411] 
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood 
pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 
prospective studies. Lancet. 2002; 360:1903–1913. [PubMed: 12493255] 
Franceschini et al. Page 9













5. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-
stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005; 165:923–
928. [PubMed: 15851645] 
6. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. 
Lancet. 2008; 371:1513–1518. [PubMed: 18456100] 
7. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic 
hypertension. Final results of the systolic hypertension in the elderly program (SHEP). Shep 
Cooperative Research group. JAMA. 1991; 265:3255–3264. [PubMed: 2046107] 
8. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of 
persons with high blood pressure, including mild hypertension. Hypertension detection and follow-
up program cooperative group. JAMA. 1979; 242:2562–2571. [PubMed: 490882] 
9. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood 
pressure averaging 90 through 114 mm Hg. JAMA. 1970; 213:1143–1152. [PubMed: 4914579] 
10. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised 
double-blind comparison of placebo and active treatment for older patients with isolated systolic 
hypertension. The Systolic Hypertension in Europe (syst-eur) Trial Investigators. Lancet. 1997; 
350:757–764. [PubMed: 9297994] 
11. MRC trial of treatment of mild hypertension: principal results. Medical research council working 
party. Br Med J (Clin Res Ed). 1985; 291:97–104.
12. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker 
oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). 
The IPPPSH Collaborative Group. J Hypertens. 1985; 3:379–392. [PubMed: 2864374] 
13. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and 
classification of chronic kidney disease: a position statement from kidney disease: improving 
global outcomes (KDIGO). Kidney Int. 2005; 67:2089–2100. [PubMed: 15882252] 
14. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure 
control among United States adults with hypertension: the National Health and Nutrition 
Examination Survey, 2001 to 2010. Circulation. 2012; 126:2105–2114. [PubMed: 23091084] 
15. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in 
the United States, 1988–2000. JAMA. 2003; 290:199–206. [PubMed: 12851274] 
16. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in 
novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 478:103–
109. [PubMed: 21909115] This is the largest GWAS of BP published. It identified 29 SNPs in 28 
loci for BP traits and hypertension. The study comprised of 69,395 individuals of European 
ancestry for discovery and approximately 200,000 individuals were included in the discovery and 
replication samples
17. Hopkins PN, Hunt SC. Genetics of hypertension. Genet Med. 2003; 5:413–429. [PubMed: 
14614392] 
18. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. 
Human hypertension caused by mutations in wnk kinases. Science. 2001; 293:1107–1112. 
[PubMed: 11498583] 
19. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association 
study of blood pressure and hypertension. Nat Genet. 2009
20. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide 
association study identifies eight loci associated with blood pressure. Nat Genet. 2009
21. Wain LV, Verwoert GC, O’Reilly PF, Shi G, Johnson T, Johnson AD, et al. Genome-wide 
association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat 
Genet. 2011; 43:1005–1011. [PubMed: 21909110] 
22. Salvi E, Kutalik Z, Glorioso N, Benaglio P, Frau F, Kuznetsova T, et al. Genomewide association 
study using a high-density single nucleotide polymorphism array and case-control design identifies 
a novel essential hypertension susceptibility locus in the promoter region of endothelial no 
synthase. Hypertension. 2012; 59:248–255. [PubMed: 22184326] 
Franceschini et al. Page 10













23. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, et al. Genome-wide 
association study of blood pressure extremes identifies variant near umod associated with 
hypertension. PLoS Genet. 2010; 6:e1001177. [PubMed: 21082022] 
24. Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W, Franceschini N, et al. Gene-centric 
meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-
related loci. Am J Hum Genet. 2014; 94:349–360. [PubMed: 24560520] 
25. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, et al. Loci influencing blood 
pressure identified using a cardiovascular gene-centric array. Hum Mol Genet. 2013; 22:1663–
1678. [PubMed: 23303523] 
26. Johnson T, Gaunt TR, Newhouse SJ, Padmanabhan S, Tomaszewski M, Kumari M, et al. Blood 
pressure loci identified with a gene-centric array. Am J Hum Genet. 2011; 89:688–700. [PubMed: 
22100073] 
27. Johnson AD, Newton-Cheh C, Chasman DI, Ehret GB, Johnson T, Rose L, et al. Association of 
hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. 
Hypertension. 2011; 57:903–910. [PubMed: 21444836] 
28. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide 
association studies identifies common variants associated with blood pressure variation in East 
Asians. Nat Genet. 2011; 43:531–538. [PubMed: 21572416] A large GWAS of East Asians. It 
identified four new loci (ST7L–CAPZA1, FIGN-GRB14, ENPEP and NPR3) and a newly 
discovered variant near TBX3. The paper compares the effect estimates for the ICBP SNPs 
between European and East Asian studies
29. Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, Ban HJ, et al. A large-scale genome-wide association 
study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat 
Genet. 2009; 41:527–534. [PubMed: 19396169] 
30. Zhu X, Young JH, Fox E, Keating BJ, Franceschini N, Kang S, et al. Combined admixture 
mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: 
contributions from the CARe consortium. Hum Mol Genet. 2011; 20(11):2285–2295. [PubMed: 
21422096] 
31. Franceschini N, Fox E, Zhang Z, Edwards TL, Nalls MA, Sung YJ, et al. Genome-wide association 
analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes 
in African and non-African populations. Am J Hum Genet. 2013; 93:545–554. [PubMed: 
23972371] This is the largest GWAS ofBP in African ancestry individuals. The study identified 
three novel loci for blood pressure traits and allelic heterogeneity in one known locus
32. Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, Cooper R, et al. Estimating African 
American admixture proportions by use of population-specific alleles. Am J Hum Genet. 1998; 
63:1839–1851. [PubMed: 9837836] 
33. Okada Y, Sim X, Go MJ, Wu JY, Gu D, Takeuchi F, et al. Metaanalysis identifies multiple loci 
associated with kidney function-related traits in East Asian populations. Nat Genet. 2012; 44:904–
909. [PubMed: 22797727] 
34. Marth GT, Yu F, Indap AR, Garimella K, Gravel S, Leong WF, et al. The functional spectrum of 
low-frequency coding variation. Genome Biol. 2011; 12:R84. [PubMed: 21917140] 
35. Sanna S, Li B, Mulas A, Sidore C, Kang HM, Jackson AU, et al. Fine mapping of five loci 
associated with low-density lipoprotein cholesterol detects variants that double the explained 
heritability. PLoS Genet. 2011; 7:e1002198. [PubMed: 21829380] 
36. Ji W, Foo JN, O’Roak BJ, Zhao H, Larson MG, Simon DB, et al. Rare independent mutations in 
renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008; 40:592–599. 
[PubMed: 18391953] 
37. Bustamante CD, Burchard EG, De la Vega FM. Genomics for the world. Nature. 2011; 475:163–
165. [PubMed: 21753830] 
38. Scaroni C, Biason A, Carpene G, Opocher G, Mantero F. 17-alpha-hydroxylase deficiency in three 
siblings: short- and long-term studies. J Endocrinol Invest. 1991; 14:99–108. [PubMed: 1648117] 
39. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a 
novel hypotensive peptide isolated from human pheochromocytoma. 1993. Biochem Biophys Res 
Commun. 2012; 425:548–555. [PubMed: 22925672] 
Franceschini et al. Page 11













40. Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma A review of the 
literature and report of one institution’s experience. Med (Baltimore). 1991; 70:46–66.
41. Wang H, Liu J, Liu K, Liu Y, Wang Z, Lou Y, et al. Beta1-adrenoceptor gene arg389gly 
polymorphism and essential hypertension risk in general population: a meta-analysis. Mol Biol 
Rep. 2013; 40:4055–4063. [PubMed: 23588958] 
42. Hunt SC, Geleijnse JM, Wu LL, Witteman JC, Williams RR, Grobbee DE. Enhanced blood 
pressure response to mild sodium reduction in subjects with the 235t variant of the 
angiotensinogen gene. Am J Hypertens. 1999; 12:460–466. [PubMed: 10342783] 
43. Svetkey LP, Moore TJ, Simons-Morton DG, Appel LJ, Bray GA, Sacks FM, et al. Angiotensinogen 
genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) 
study. J Hypertens. 2001; 19:1949–1956. [PubMed: 11677359] 
44. Wolf MB, Baynes JW. Cadmium and mercury cause an oxidative stress-induced endothelial 
dysfunction. Biometals. 2007; 20:73–81. [PubMed: 16752219] 
45. Messner B, Knoflach M, Seubert A, Ritsch A, Pfaller K, Henderson B, et al. Cadmium is a novel 
and independent risk factor for early atherosclerosis mechanisms and in vivo relevance. 
Arterioscler Thromb Vasc Biol. 2009; 29:1392–1398. [PubMed: 19556524] 
46. Staessen JA, Kuznetsova T, Roels HA, Emelianov D, Fagard R. Exposure to cadmium and 
conventional and ambulatory blood pressures in a prospective population study. Public Health and 
Environmental Exposure to Cadmium Study Group. Am J Hypertens. 2000; 13(2):146–156. 
[PubMed: 10701814] 
47. Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, Guallar E. Cadmium exposure and hypertension 
in the 1999–2004 National Health and Nutrition Examination Survey (NHANES). Environ Health 
Perspect. 2008; 116(1):51–56. [PubMed: 18197299] 
48. Kottgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, et al. Multiple loci associated with 
indices of renal function and chronic kidney disease. Nat Genet. 2009; 41:712–717. [PubMed: 
19430482] 
49. Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, et al. Common noncoding umod 
gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin 
expression. Nat Med. 2013; 19:1655–1660. [PubMed: 24185693] 
50. Freedman BI, Murea M. Target organ damage in African American hypertension: role of APOL1. 
Curr Hypertens Rep. 2012; 14:21–28. [PubMed: 22068337] 
51. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of 
trypanolytic apol1 variants with kidney disease in African Americans. Science. 2010; 329:841–
845. [PubMed: 20647424] 
52. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, et al. MYH9 is associated with 
nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008; 40:1185–1192. 
[PubMed: 18794854] 
53. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, et al. MYH9 is a 
major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008; 40:1175–1184. 
[PubMed: 18794856] 
54. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, et al. Use of genome-wide 
association studies for drug repositioning. Nat Biotechnol. 2012; 30:317–320. [PubMed: 
22491277] 
55. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, et al. 
Pharmacogenetic association of the NPPA t2238c genetic variant with cardiovascular disease 
outcomes in patients with hypertension. JAMA. 2008; 299:296–307. [PubMed: 18212314] 
56. Luo F, Wang Y, Wang X, Sun K, Zhou X, Hui R. A functional variant of nedd4l is associated with 
hypertension, antihypertensive response, and orthostatic hypotension. Hypertension. 2009; 
54:796–801. [PubMed: 19635985] 
57. Manunta P, Lavery G, Lanzani C, Braund PS, Simonini M, Bodycote C, et al. Physiological 
interaction between alpha-adducin and wnk1-nedd4l pathways on sodium-related blood pressure 
regulation. Hypertension. 2008; 52:366–372. [PubMed: 18591455] 
Franceschini et al. Page 12













58. Svensson-Farbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, et al. A functional 
variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers 
and diuretics in hypertensive patients. JHypertens. 2011; 29:388–395. [PubMed: 21052022] 
59. Turner ST, Boerwinkle E, O’Connell JR, Bailey KR, Gong Y, Chapman AB, et al. Genomic 
association analysis of common variants influencing antihypertensive response to 
hydrochlorothiazide. Hypertension. 2013; 62:391–397. [PubMed: 23753411] Two recent GWAS 
of blood response to antihypertensive drugs
60. Arnett DK, Claas SA. Pharmacogenetics of antihypertensive treatment: detailing disciplinary 
dissonance. Pharmacogenomics. 2009; 10:1295–1307. [PubMed: 19663674] 
61. Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med. 2012; 
44(Suppl 1):S17–S22. [PubMed: 22713143] 
62. Gong Y, McDonough CW, Wang Z, Hou W, Cooper-DeHoff RM, Langaee TY, et al. Hypertension 
susceptibility loci and blood pressure response to antihypertensives: results from the 
pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012; 
5:686–691. [PubMed: 23087401] Two recent GWAS of blood response to antihypertensive drugs
63. He J, Kelly TN, Zhao Q, Li H, Huang J, Wang L, et al. Genome-wide association study identifies 8 
novel loci associated with blood pressure responses to interventions in Han Chinese. Circ 
Cardiovasc Genet. 2013; 6:598–607. [PubMed: 24165912] 
64. Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, Chapman AB, Gums JG, Bailey K, et al. 
Genome-wide association analyses suggest nell1 influences adverse metabolic response to hctz in 
African Americans. Pharmacogenomics J. 2014; 14:35–40. [PubMed: 23400010] 
65. Gong Y, McDonough CW, Beitelshees AL, Karnes JH, O’Connell JR, Turner ST, et al. PROX1 
gene variant is associated with fasting glucose change after antihypertensive treatment. 
Pharmacotherapy. 2014; 34:123–130. [PubMed: 24122840] 
66. McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, et al. 
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive 
responses (PEAR) Study. PLoS ONE. 2013; 8(10):e76984. [PubMed: 24116192] 
67. Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, et al. Genetic variants 
associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet 
Genomics. 2013; 23:470–478. [PubMed: 23838604] 
68. Karnes JH, Gong Y, Pacanowski MA, McDonough CW, Arwood MJ, Langaee TY, et al. Impact of 
TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. 
Pharmacogenet Genomics. 2013; 23:697–705. [PubMed: 24128935] 
69. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 
evidence-based guideline for the management of high blood pressure in adults: report from the 
panel members appointed to the eighth joint national committee (jnc 8). JAMA. 2014; 311:507–
520. [PubMed: 24352797] 
70. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme 
inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment 
to prevent heart attack trial (allhat). JAMA. 2002; 288:2981–2997. [PubMed: 12479763] 
71. Luft FC, Miller JZ, Grim CE, Fineberg NS, Christian JC, Daugherty SA, et al. Salt sensitivity 
resistance of blood pressure. Age and race as factors in physiological responses. Hypertension. 
1991; 17:I102–I108. [PubMed: 1846122] 
72. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996; 27:481–490. 
[PubMed: 8613190] 
73. Tu W, Eckert GJ, Hannon TS, Liu H, Pratt LM, Wagner MA, et al. Racial differences in sensitivity 
of blood pressure to aldosterone. Hypertension. 2014
Franceschini et al. Page 13

























Franceschini et al. Page 14
Table 1
Loci with genes in known blood pressure pathways identified in genome-wide association studies in the 
general population and their pharmacologic targets
Loci with genes related to BP pathways Pharmacologic targets
Neuroendocrine system
    CYP17A1(cytochrome P450 enzyme)
    ADM (adrenomedullin)
    ADRB1 (adrenoceptor beta 1) [21] Primary target for β-adrenergic receptor blockers
Vasoactive peptides
    NPPA/NPPB (precursors of atrial- and B-type natriuretic peptides)
    NPR3 (natriuretic peptide receptor 3)
    EDN3 (endothelin 3)
Nitric oxide pathways
    GUCY1A3-GUCY1B3 (alpha and beta subunits of soluble
guanylate cyclase)
Isosorbide dinitrate is a nitric oxide donor and hydralazine prevents 
nitric oxide
degradation
    NOS3 (nitric oxide synthase 3 (endothelial cell))
Calcium and potassium channels
    ATP2B1 (ATPase, Ca++ transporting, plasma membrane 1)
    CACNB2 (calcium channel, voltage-dependent, beta 2 subunit) Controls the cell surface expression of the α1c subunit to which 
calcium channel
blockers bind
    KCNJ11 (potassium inwardly-rectifying channel, subfamily J,
member 11) [24]
Target of verapamil and glyburide
Renin-angiotensin system
    ENPEP (glutamyl aminopeptidase) [28•]
    AGT (angiotensinogen)
    FURIN (furin (paired basic amino acid cleaving enzyme)
Wnt/beta-catenin signaling pathways
    RSPO3 (R-spondin 3) [31 •]
Kidney solute transport
    SLC4A7 (electro-neutral sodium bicarbonate co-transporter)
    SLC39A8 (solute carrier family 39 [zinc transporter], member 8)
Kidney structure or proteins
    UMOD (uromodulin) Potential target of furosemide (see text)
    PLCE1 (phospholipase C, epsilon 1)
Unknown pathways
    RELA (v-rel avian reticuloendotheliosis viral oncogene homolog
A) [24]
Antihypertensive olmesartan and disulfiram
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